Doximity, Inc. $DOCS Shares Newly Purchased by Vise Technologies Inc.

Vise Technologies Inc. bought a new position in shares of Doximity, Inc. (NYSE:DOCS) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 18,426 shares of the company’s stock, valued at approximately $522,000.

Other large investors have also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its holdings in shares of Doximity by 10.4% in the 3rd quarter. Signaturefd LLC now owns 4,205 shares of the company’s stock worth $119,000 after purchasing an additional 397 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Doximity by 59.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock worth $53,000 after purchasing an additional 695 shares during the last quarter. Apella Capital LLC grew its holdings in Doximity by 1.4% in the 3rd quarter. Apella Capital LLC now owns 59,488 shares of the company’s stock worth $1,647,000 after buying an additional 802 shares in the last quarter. GAMMA Investing LLC grew its holdings in Doximity by 19.8% in the 3rd quarter. GAMMA Investing LLC now owns 5,834 shares of the company’s stock worth $165,000 after buying an additional 963 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in Doximity by 111.0% in the 1st quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after acquiring an additional 1,347 shares during the period. 87.19% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DOCS. Barclays lifted their price objective on shares of Doximity from $27.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday. Wells Fargo & Company downgraded Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 target price for the company. in a research report on Monday, August 10th. Wolfe Research upgraded Doximity to an “outperform” rating in a research report on Thursday, August 13th. Weiss Ratings upgraded shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, October 6th. Finally, Truist Financial raised their price objective on shares of Doximity from $19.00 to $24.00 and gave the company a “hold” rating in a research report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $30.59.

Insider Transactions at Doximity

In related news, CAO Siddharth Sitaram sold 2,613 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the sale, the chief accounting officer owned 101,432 shares of the company’s stock, valued at approximately $3,111,933.76. The trade was a 2.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy Cabral sold 10,721 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $35.00, for a total transaction of $375,235.00. Following the completion of the sale, the director directly owned 8,084 shares of the company’s stock, valued at $282,940. This represents a 57.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 22,701 shares of company stock valued at $717,401. 31.80% of the stock is currently owned by company insiders.

Doximity Trading Up 2.8%

Shares of DOCS stock opened at $33.34 on Thursday. The company has a market capitalization of $5.94 billion, a price-to-earnings ratio of 42.10, a P/E/G ratio of 33.78 and a beta of 1.29. Doximity, Inc. has a 1-year low of $17.15 and a 1-year high of $53.46. The stock’s fifty day simple moving average is $29.47 and its 200-day simple moving average is $25.40.

Doximity (NYSE:DOCS) last issued its earnings results on Thursday, November 5th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.17. The company had revenue of $174.54 million for the quarter. Doximity had a return on equity of 15.80% and a net margin of 21.12%. Doximity’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 EPS. On average, sell-side analysts predict that Doximity, Inc. will post 0.74 EPS for the current year.

Key Stories Impacting Doximity

Here are a few of the latest stories about DOCS:

• Positive Sentiment: Doximity rolled out DoseCheck, a product highlighted in connection with near-zero drug-dosing errors. The launch could add value to its clinical workflow offerings, although the report provided no revenue outlook or adoption figures. Article: Doximity Rolls Out DoseCheck
• Neutral Sentiment: Barclays raised its price target from $27 to $30 but kept an “equal weight” rating. The higher target is a modest positive, though it remains below the $33.34 price cited in the supplied market data, signaling limited upside at that level. Article: Barclays price target
• Negative Sentiment: Several law firms reiterated a securities class action and the November 16 lead-plaintiff deadline. The suit alleges Doximity misled investors about Newsfeed engagement, competition, advertising formats and revenue performance; these claims are allegations, not proven findings. The litigation may sustain uncertainty and reputational risk. Article: Doximity class-action reminder

About Doximity

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.